As a traditional Chinese medicine (TCM), borneol has shown superior ability for anti-inflammatory and analgesic activities when coupled with other active ingredients from ancient times. Furthermore, borneol is believed to improve blood concentration and bioavailability of drugs. Thus, it has been paired with various TCM formulas since ancient time. The physiological barriers in human can cause significant limitations in drug efficiency as the drug is primarily restricted from entering into blood and brain. Borneol has been proven to enhance the permeability of biological barriers such as the blood-brain, transdermal, corneal, and intestinal barriers. Moreover, growing interest has been shown in the drug delivery system design for trans-barrier transport involving borneol. Nano-drug delivery system with increased surface area and improved active sites, has been applied to increase the bioactivity of water insoluble drugs. Nano-drug delivery system has been used to enhance drug efficacy by reducing the time of action as compared to conventional administration approach of TCM formulas. Given its ability to enhance cross-barrier permeation and drug efficacy, borneol has been integrated into TCM formulas of drug delivery system for precise and prolonged targeting at tumor sites. However, the design and preparation of a drug delivery system consisting of borneol still face great challenges. Current research fails to unravel the difference in mechanism of action between nano-drug delivery systems comprised of borneol and conventional drug systems coupled with borneol. Enhanced penetration of borneol in drug delivery system is rarely verified compared to conventional administration with identical drug formulation consisting of borneol regarding dosage and medical indications. This study outlines the current state of research on the properties, formulation and pharmacological effects of borneol, allowing cross-comparison of borneol coupled with single compound and classical TCM formulas for various medical indications. This study aims to provide insights into the design of borneol-based enhanced cross-barrier delivery drug formulation, and the potential development of nano-drug system for TCM formulas with borneol for enhanced bioavailability.

Depression is a severe mental illness. Although existing antidepressant medications have shown efficacy in many patients, a significant proportion show poor responses to current treatments, necessitating the need for novel therapeutic approaches. Photobiomodulation (PBM), an emerging physical therapy, has recently shown promising efficacy in the treatment of depression, as indicated by two systematic reviews, and is characterized by high safety and good tolerability. However, challenges remain in areas such as light delivery techniques and optimization of treatment parameters. This review summarizes the antidepressant mechanisms of PBM, various methods of light transmission, and recent research progress on its application in the treatment of depression. It also discusses issues related to safety, tolerability, and impact of specific parameters, aiming to provide insights and recommendations for future research on PBM as a therapy for depression.

Depression is a severe mental illness. Although existing antidepressant medications have shown efficacy in many patients, a significant proportion show poor responses to current treatments, necessitating the need for novel therapeutic approaches. Photobiomodulation (PBM), an emerging physical therapy, has recently shown promising efficacy in the treatment of depression, as indicated by two systematic reviews, and is characterized by high safety and good tolerability. However, challenges remain in areas such as light delivery techniques and optimization of treatment parameters. This review summarizes the antidepressant mechanisms of PBM, various methods of light transmission, and recent research progress on its application in the treatment of depression. It also discusses issues related to safety, tolerability, and impact of specific parameters, aiming to provide insights and recommendations for future research on PBM as a therapy for depression.

Objective:To compare the short-term efficacy of robotic-assisted sacrocolpopexy(RASC)and lap-aroscopic sacrocolpopexy(LSC)in overweight/obese patients with pelvic organ prolapse(POP),and to evaluate the advantages of RASC.Methods:We retrospectively collected the clinical data of overweight/obese(body mass index≥24 kg/m2)patients over 50 years old with POP who underwent sacrocolpopexy in the Department of Gynecology of the First Affiliated Hospital of Zhengzhou University from November 2014 to June 2023.According to the surgical method,they were divided into robotic group(68 cases)and laparoscopic group(110 cases).The intraoperative,postoperative and short-term follow-up outcomes of the two groups were compared.Pelvic Floor Distress Inventory-short form 20(PFDI-20),Pelvic Floor Impact Questionnaire-short form 7(PFIQ-7)and the Patient Global Impression of Improvement(PGI-Ⅰ)were used to evaluate surgical outcomes.Results:①No intra-operative conversion to laparotomy was found in both groups.Compared with the laparoscopic group,the robotic group had shorter operation time,less intraoperative blood loss,shorter postoperative anal exhaust time,and shor-ter postoperative hospital stay.The difference was statistically significant(P＜0.05).②There were no intraopera-tive complications in the robot group.While in the laparoscopic group,there was 1 case of bladder injury.③Within the two groups,the PFDI-20 and PFIQ-7 scores at 3 and 12 months after surgery were lower than those before surgery,and the difference was statistically significant(P＜0.05).PGI-Ⅰ scores were both"significantly im-proved".Subjective and objective cure rate were 100％.④The POP-Q indicator points(Aa,Ba,C,Ap,Bp,gh,pb,TVL)of both groups at 3 and 12 months after surgery were better than those before surgery(P＜0.05),achie-ving satisfactory anatomical reduction.Conclusions:RASC is safe and feasible in the treatment of overweight and obese patients with POP.Compared to LSC,RASC has significantly shorter operation time,less blood loss,faster postoperative intestinal function recovery,shorter postoperative hospital stay,and stable short-term effect.Therefore,RASC can provide a new choice for overweight/obese patients with POP.

Objective:To compare the short-term efficacy of robotic-assisted sacrocolpopexy(RASC)and lap-aroscopic sacrocolpopexy(LSC)in overweight/obese patients with pelvic organ prolapse(POP),and to evaluate the advantages of RASC.Methods:We retrospectively collected the clinical data of overweight/obese(body mass index≥24 kg/m2)patients over 50 years old with POP who underwent sacrocolpopexy in the Department of Gynecology of the First Affiliated Hospital of Zhengzhou University from November 2014 to June 2023.According to the surgical method,they were divided into robotic group(68 cases)and laparoscopic group(110 cases).The intraoperative,postoperative and short-term follow-up outcomes of the two groups were compared.Pelvic Floor Distress Inventory-short form 20(PFDI-20),Pelvic Floor Impact Questionnaire-short form 7(PFIQ-7)and the Patient Global Impression of Improvement(PGI-Ⅰ)were used to evaluate surgical outcomes.Results:①No intra-operative conversion to laparotomy was found in both groups.Compared with the laparoscopic group,the robotic group had shorter operation time,less intraoperative blood loss,shorter postoperative anal exhaust time,and shor-ter postoperative hospital stay.The difference was statistically significant(P＜0.05).②There were no intraopera-tive complications in the robot group.While in the laparoscopic group,there was 1 case of bladder injury.③Within the two groups,the PFDI-20 and PFIQ-7 scores at 3 and 12 months after surgery were lower than those before surgery,and the difference was statistically significant(P＜0.05).PGI-Ⅰ scores were both"significantly im-proved".Subjective and objective cure rate were 100％.④The POP-Q indicator points(Aa,Ba,C,Ap,Bp,gh,pb,TVL)of both groups at 3 and 12 months after surgery were better than those before surgery(P＜0.05),achie-ving satisfactory anatomical reduction.Conclusions:RASC is safe and feasible in the treatment of overweight and obese patients with POP.Compared to LSC,RASC has significantly shorter operation time,less blood loss,faster postoperative intestinal function recovery,shorter postoperative hospital stay,and stable short-term effect.Therefore,RASC can provide a new choice for overweight/obese patients with POP.

Objective:To compare the short-term efficacy of robotic-assisted sacrocolpopexy(RASC)and lap-aroscopic sacrocolpopexy(LSC)in overweight/obese patients with pelvic organ prolapse(POP),and to evaluate the advantages of RASC.Methods:We retrospectively collected the clinical data of overweight/obese(body mass index≥24 kg/m2)patients over 50 years old with POP who underwent sacrocolpopexy in the Department of Gynecology of the First Affiliated Hospital of Zhengzhou University from November 2014 to June 2023.According to the surgical method,they were divided into robotic group(68 cases)and laparoscopic group(110 cases).The intraoperative,postoperative and short-term follow-up outcomes of the two groups were compared.Pelvic Floor Distress Inventory-short form 20(PFDI-20),Pelvic Floor Impact Questionnaire-short form 7(PFIQ-7)and the Patient Global Impression of Improvement(PGI-Ⅰ)were used to evaluate surgical outcomes.Results:①No intra-operative conversion to laparotomy was found in both groups.Compared with the laparoscopic group,the robotic group had shorter operation time,less intraoperative blood loss,shorter postoperative anal exhaust time,and shor-ter postoperative hospital stay.The difference was statistically significant(P＜0.05).②There were no intraopera-tive complications in the robot group.While in the laparoscopic group,there was 1 case of bladder injury.③Within the two groups,the PFDI-20 and PFIQ-7 scores at 3 and 12 months after surgery were lower than those before surgery,and the difference was statistically significant(P＜0.05).PGI-Ⅰ scores were both"significantly im-proved".Subjective and objective cure rate were 100％.④The POP-Q indicator points(Aa,Ba,C,Ap,Bp,gh,pb,TVL)of both groups at 3 and 12 months after surgery were better than those before surgery(P＜0.05),achie-ving satisfactory anatomical reduction.Conclusions:RASC is safe and feasible in the treatment of overweight and obese patients with POP.Compared to LSC,RASC has significantly shorter operation time,less blood loss,faster postoperative intestinal function recovery,shorter postoperative hospital stay,and stable short-term effect.Therefore,RASC can provide a new choice for overweight/obese patients with POP.

Objective:To compare the short-term efficacy of robotic-assisted sacrocolpopexy(RASC)and lap-aroscopic sacrocolpopexy(LSC)in overweight/obese patients with pelvic organ prolapse(POP),and to evaluate the advantages of RASC.Methods:We retrospectively collected the clinical data of overweight/obese(body mass index≥24 kg/m2)patients over 50 years old with POP who underwent sacrocolpopexy in the Department of Gynecology of the First Affiliated Hospital of Zhengzhou University from November 2014 to June 2023.According to the surgical method,they were divided into robotic group(68 cases)and laparoscopic group(110 cases).The intraoperative,postoperative and short-term follow-up outcomes of the two groups were compared.Pelvic Floor Distress Inventory-short form 20(PFDI-20),Pelvic Floor Impact Questionnaire-short form 7(PFIQ-7)and the Patient Global Impression of Improvement(PGI-Ⅰ)were used to evaluate surgical outcomes.Results:①No intra-operative conversion to laparotomy was found in both groups.Compared with the laparoscopic group,the robotic group had shorter operation time,less intraoperative blood loss,shorter postoperative anal exhaust time,and shor-ter postoperative hospital stay.The difference was statistically significant(P＜0.05).②There were no intraopera-tive complications in the robot group.While in the laparoscopic group,there was 1 case of bladder injury.③Within the two groups,the PFDI-20 and PFIQ-7 scores at 3 and 12 months after surgery were lower than those before surgery,and the difference was statistically significant(P＜0.05).PGI-Ⅰ scores were both"significantly im-proved".Subjective and objective cure rate were 100％.④The POP-Q indicator points(Aa,Ba,C,Ap,Bp,gh,pb,TVL)of both groups at 3 and 12 months after surgery were better than those before surgery(P＜0.05),achie-ving satisfactory anatomical reduction.Conclusions:RASC is safe and feasible in the treatment of overweight and obese patients with POP.Compared to LSC,RASC has significantly shorter operation time,less blood loss,faster postoperative intestinal function recovery,shorter postoperative hospital stay,and stable short-term effect.Therefore,RASC can provide a new choice for overweight/obese patients with POP.

Objective:To compare the short-term efficacy of robotic-assisted sacrocolpopexy(RASC)and lap-aroscopic sacrocolpopexy(LSC)in overweight/obese patients with pelvic organ prolapse(POP),and to evaluate the advantages of RASC.Methods:We retrospectively collected the clinical data of overweight/obese(body mass index≥24 kg/m2)patients over 50 years old with POP who underwent sacrocolpopexy in the Department of Gynecology of the First Affiliated Hospital of Zhengzhou University from November 2014 to June 2023.According to the surgical method,they were divided into robotic group(68 cases)and laparoscopic group(110 cases).The intraoperative,postoperative and short-term follow-up outcomes of the two groups were compared.Pelvic Floor Distress Inventory-short form 20(PFDI-20),Pelvic Floor Impact Questionnaire-short form 7(PFIQ-7)and the Patient Global Impression of Improvement(PGI-Ⅰ)were used to evaluate surgical outcomes.Results:①No intra-operative conversion to laparotomy was found in both groups.Compared with the laparoscopic group,the robotic group had shorter operation time,less intraoperative blood loss,shorter postoperative anal exhaust time,and shor-ter postoperative hospital stay.The difference was statistically significant(P＜0.05).②There were no intraopera-tive complications in the robot group.While in the laparoscopic group,there was 1 case of bladder injury.③Within the two groups,the PFDI-20 and PFIQ-7 scores at 3 and 12 months after surgery were lower than those before surgery,and the difference was statistically significant(P＜0.05).PGI-Ⅰ scores were both"significantly im-proved".Subjective and objective cure rate were 100％.④The POP-Q indicator points(Aa,Ba,C,Ap,Bp,gh,pb,TVL)of both groups at 3 and 12 months after surgery were better than those before surgery(P＜0.05),achie-ving satisfactory anatomical reduction.Conclusions:RASC is safe and feasible in the treatment of overweight and obese patients with POP.Compared to LSC,RASC has significantly shorter operation time,less blood loss,faster postoperative intestinal function recovery,shorter postoperative hospital stay,and stable short-term effect.Therefore,RASC can provide a new choice for overweight/obese patients with POP.

Objective:To compare the short-term efficacy of robotic-assisted sacrocolpopexy(RASC)and lap-aroscopic sacrocolpopexy(LSC)in overweight/obese patients with pelvic organ prolapse(POP),and to evaluate the advantages of RASC.Methods:We retrospectively collected the clinical data of overweight/obese(body mass index≥24 kg/m2)patients over 50 years old with POP who underwent sacrocolpopexy in the Department of Gynecology of the First Affiliated Hospital of Zhengzhou University from November 2014 to June 2023.According to the surgical method,they were divided into robotic group(68 cases)and laparoscopic group(110 cases).The intraoperative,postoperative and short-term follow-up outcomes of the two groups were compared.Pelvic Floor Distress Inventory-short form 20(PFDI-20),Pelvic Floor Impact Questionnaire-short form 7(PFIQ-7)and the Patient Global Impression of Improvement(PGI-Ⅰ)were used to evaluate surgical outcomes.Results:①No intra-operative conversion to laparotomy was found in both groups.Compared with the laparoscopic group,the robotic group had shorter operation time,less intraoperative blood loss,shorter postoperative anal exhaust time,and shor-ter postoperative hospital stay.The difference was statistically significant(P＜0.05).②There were no intraopera-tive complications in the robot group.While in the laparoscopic group,there was 1 case of bladder injury.③Within the two groups,the PFDI-20 and PFIQ-7 scores at 3 and 12 months after surgery were lower than those before surgery,and the difference was statistically significant(P＜0.05).PGI-Ⅰ scores were both"significantly im-proved".Subjective and objective cure rate were 100％.④The POP-Q indicator points(Aa,Ba,C,Ap,Bp,gh,pb,TVL)of both groups at 3 and 12 months after surgery were better than those before surgery(P＜0.05),achie-ving satisfactory anatomical reduction.Conclusions:RASC is safe and feasible in the treatment of overweight and obese patients with POP.Compared to LSC,RASC has significantly shorter operation time,less blood loss,faster postoperative intestinal function recovery,shorter postoperative hospital stay,and stable short-term effect.Therefore,RASC can provide a new choice for overweight/obese patients with POP.

Objective:To compare the short-term efficacy of robotic-assisted sacrocolpopexy(RASC)and lap-aroscopic sacrocolpopexy(LSC)in overweight/obese patients with pelvic organ prolapse(POP),and to evaluate the advantages of RASC.Methods:We retrospectively collected the clinical data of overweight/obese(body mass index≥24 kg/m2)patients over 50 years old with POP who underwent sacrocolpopexy in the Department of Gynecology of the First Affiliated Hospital of Zhengzhou University from November 2014 to June 2023.According to the surgical method,they were divided into robotic group(68 cases)and laparoscopic group(110 cases).The intraoperative,postoperative and short-term follow-up outcomes of the two groups were compared.Pelvic Floor Distress Inventory-short form 20(PFDI-20),Pelvic Floor Impact Questionnaire-short form 7(PFIQ-7)and the Patient Global Impression of Improvement(PGI-Ⅰ)were used to evaluate surgical outcomes.Results:①No intra-operative conversion to laparotomy was found in both groups.Compared with the laparoscopic group,the robotic group had shorter operation time,less intraoperative blood loss,shorter postoperative anal exhaust time,and shor-ter postoperative hospital stay.The difference was statistically significant(P＜0.05).②There were no intraopera-tive complications in the robot group.While in the laparoscopic group,there was 1 case of bladder injury.③Within the two groups,the PFDI-20 and PFIQ-7 scores at 3 and 12 months after surgery were lower than those before surgery,and the difference was statistically significant(P＜0.05).PGI-Ⅰ scores were both"significantly im-proved".Subjective and objective cure rate were 100％.④The POP-Q indicator points(Aa,Ba,C,Ap,Bp,gh,pb,TVL)of both groups at 3 and 12 months after surgery were better than those before surgery(P＜0.05),achie-ving satisfactory anatomical reduction.Conclusions:RASC is safe and feasible in the treatment of overweight and obese patients with POP.Compared to LSC,RASC has significantly shorter operation time,less blood loss,faster postoperative intestinal function recovery,shorter postoperative hospital stay,and stable short-term effect.Therefore,RASC can provide a new choice for overweight/obese patients with POP.